Relay Therapeutics Q2 2026 earnings: Clinical spending rises with cash runway into 2029

Relay Therapeutics’ Q2 2026 revenue fell to $0.4 million from $0.7 million, while net loss widened to $83.7 million and loss per share remained $0.41. R&D expense rose 20% to $76.5 million as spending increased across zovegalisib clinical trials. Cash, cash equivalents and investments reached $910.9 million after the May follow-on offering, supporting an expected runway into 2029. Relay also reported a 44% response rate for a zovegalisib triplet in heavily pretreated breast cancer patients and opened vascular-anomaly expansion cohorts.